John V. Heymach, MD, PhD, on First-Line Therapy for Advanced NSCLC With EGFR Exon 20 Insertions

June 04, 2026 By The ASCO Post Staff

John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the primary analysis of the multinational phase III WU-KONG28 trial, which looked at sunvozertinib monotherapy vs platinum-based therapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) and EGFR exon 20 insertions (Abstract LBA8500). 

Related Content